CAMBRIDGE, England & TEL AVIV, Israel–(BUSINESS WIRE)–Undecimal Bio (“Undecimal”), a platform biotechnology company advancing targeted delivery of siRNA therapeutics, today announced an oversubscribed $18 million USD seed financing. The Company, a spin-out from Eleven Therapeutics, will use the funding to expand DELiveri®, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types, addressing a major constraint in genetic medicine deliver
